Daniel Skovronsky - 10 Feb 2025 Form 4 Insider Report for ELI LILLY & Co (LLY)

Role
EVP, CSO & Pres. LRL & LLY Imm
Signature
/s/ Jonathan Groff for Daniel Skovronsky, pursuant to authorization on file
Issuer symbol
LLY
Transactions as of
10 Feb 2025
Net transactions value
+$11,994,335
Form type
4
Filing time
12 Feb 2025, 16:15:38 UTC
Previous filing
04 Feb 2025
Next filing
06 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LLY Common Stock Sale $3,407,626 -3,950 -3.2% $862.69 118,938 10 Feb 2025 Direct F1, F2
transaction LLY Common Stock Sale $293,750 -340 -0.29% $863.97 118,598 10 Feb 2025 Direct F1, F2
transaction LLY Common Stock Sale $614,690 -710 -0.6% $865.76 117,888 10 Feb 2025 Direct F1, F2
transaction LLY Common Stock Award $16,310,400 +18,772 +16% $868.88 136,660 10 Feb 2025 Direct
holding LLY Common Stock 72,359 10 Feb 2025 By Trust F3
holding LLY Common Stock 3,257 10 Feb 2025 By spouse F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LLY Restricted Stock Unit Award $0 +12,684 $0.000000 12,684 10 Feb 2025 Common Stock 12,684 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4 Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.